Compare AAME & LITS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AAME | LITS |
|---|---|---|
| Founded | 1968 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Life Insurance | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.6M | 55.9M |
| IPO Year | N/A | N/A |
| Metric | AAME | LITS |
|---|---|---|
| Price | $3.06 | $1.51 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 31.1K | ★ 795.4K |
| Earning Date | 11-14-2025 | 02-11-2026 |
| Dividend Yield | ★ 0.69% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.23 | N/A |
| Revenue | ★ $208,218,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.91 | ★ N/A |
| Revenue Growth | ★ 11.99 | N/A |
| 52 Week Low | $1.25 | $1.30 |
| 52 Week High | $3.71 | $9.00 |
| Indicator | AAME | LITS |
|---|---|---|
| Relative Strength Index (RSI) | 60.47 | N/A |
| Support Level | $2.59 | N/A |
| Resistance Level | $3.15 | N/A |
| Average True Range (ATR) | 0.28 | 0.00 |
| MACD | 0.05 | 0.00 |
| Stochastic Oscillator | 75.56 | 0.00 |
Atlantic American Corp operates in specialty markets within the life and health and property and casualty insurance industries. The company has two segments: American Southern, It provides property and casualty insurance including bodily injury and property damage liability coverage, uninsured motorist coverage, and physical damage coverage for commercial accounts, and Bankers Fidelity, the company's life and health operations offer a variety of life and supplemental health products including ordinary and term life insurance, Medicare supplement, and other health insurance.
Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients.